These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8379024)

  • 21. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy in metastatic cancer of the kidney].
    Escudier B
    Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
    Sherry RM; Pass HI; Rosenberg SA; Yang JC
    Cancer; 1992 Apr; 69(7):1850-5. PubMed ID: 1551067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
    Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
    Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells.
    Kruit WH; Schmitz PI; Stoter G
    Cancer Immunol Immunother; 1999 Sep; 48(6):331-5. PubMed ID: 10473808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
    Fallick ML; McDermott DF; LaRock D; Long JP; Atkins MB
    J Urol; 1997 Nov; 158(5):1691-5. PubMed ID: 9334580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.
    Bex A; Horenblas S; Meinhardt W; Verra N; de Gast GC
    Eur Urol; 2002 Dec; 42(6):570-4; discussion 575-6. PubMed ID: 12477652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
    Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
    Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.